Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage

Neurological Research

Volumn 32, Issue 8, 2010, Pages 873-878

  Nishino, Akio ^a   Umegaki, Masao ^a   Fujinaka, Toshiyuki ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

CEREBRAL VASOSPASM; CILOSTAZOL; SAH; SUBARACHNOID HEMORRHAGE

Indexed keywords

CILOSTAZOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BASILAR ARTERY; BLOOD VESSEL WALL; BRAIN VASOSPASM; CELL INFILTRATION; CLINICAL EVALUATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; SUBARACHNOID HEMORRHAGE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; NEUROPROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SUBARACHNOID HEMORRHAGE; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 77956602431     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164109X12608733393791     Document Type: Article

References (35)

1. Hirashima Y, Kurimoto M, Takaba M, et al. The use of computed tomography in the prediction of delayed cerebral infarction following acute aneurysm surgery for subarachnoid haemorrhage. Acta Neurochir (Wien) 1995; 132: 9-13
2. Ratsep T, Asser T. Cerebral hemodynamic impairment after aneurysmal subarachnoid hemorrhage as evaluated using transcranial Doppler ultrasonography: Relationship to delayed cerebral ischemia and clinical outcome. J Neurosurg 2001; 95: 393-401
3. Rabinstein AA, Friedman JA, Weigand SD, et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004; 35: 1862-1866
4. Mocco J, Zacharia BE, Komotar RJ, et al. A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006; 21: E9
5. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery 2003; 53: 123-133
6. Wellman GC. Ion channels and calcium signaling in cerebral arteries following subarachnoid hemorrhage. Neurol Res 2006; 28: 690-702
7. Ostrowski RP, Colohan AR, Zhang JH. Molecular mechanisms of early brain injury after subarachnoid hemorrhage. Neurol Res 2006; 28: 399-414
8. Iseda K, Ono S, Onoda K, et al. Antivasospastic and antiinflammatory effects of caspase inhibitor in experimental subarachnoid hemorrhage. J Neurosurg 2007; 107: 128-135
9. Pluta RM. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Neurol Res 2006; 28: 730-737
10. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144-1149
11. Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res 2006; 43: 86-94
12. Weintraub WS. The vascular effects of cilostazol. Can J Cardiol 2006; 22 (Suppl. B): S56B-S60B
13. Gao L, Wang F, Wang B, et al. Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther 2006; 318: 53-58
14. Kim MJ, Lee JH, Park SY, et al. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via CAMP-dependent protein kinase activation. Pharmacol Res 2006; 54: 261-267
15. Ye YL, Shi WZ, Zhang WP, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. Eur J Pharmacol 2007; 557: 23-31
16. Gules I, Satoh M, Clower BR, et al. Comparison of three rat models of cerebral vasospasm. Am J Physiol Heart Circ Physiol 2002; 283: H2551-H2559
17. Iyonaga K, Takeya M, Yamamoto T, et al. A novel monoclonal antibody, RM-4, specifically recognizes rat macrophages and dendritic cells in formalin-fixed, paraffin-embedded tissues. Histochem J 1997; 29: 105-116
18. Tanaka K, Gotoh F, Fukuuchi Y, et al. Effects of a selective inhibitor of cyclic amp phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989; 20: 668-673
19. i and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998; 123: 869-878
20. Aizawa T, Wei H, Miano JM, et al. Role of phosphodiesterase 3 in NO/CGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003; 93: 406-413
21. Watanabe T, Zhang N, Liu M, et al. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006; 37: 1539-1545
22. Lee JH, Oh GT, Park SY, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005; 313: 502-509
23. Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 1998; 29: 1930-1935
24. Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 2002; 88: 227-249
25. Mack WJ,Mocco J, Hoh DJ, et al. Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 96: 71-75
26. Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2003; 99: 376-382
27. Birk S, Kruuse C, Petersen KA, et al. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004; 24: 1352-1358
28. Birk S, Edvinsson L, Olesen J, et al. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol 2004; 489: 93-100
29. Jackowski A, Crockard A, Burnstock G, et al. The time course of intracranial pathophysiological changes following experimental subarachnoid haemorrhage in the rat. J Cereb Blood Flow Metab 1990; 10: 835-849
30. Meguro T, Clower BR, Carpenter R, et al. Improved rat model for cerebral vasospasm studies. Neurol Res 2001; 23: 761-766
31. Kim KY, Shin HK, Choi JM, et al. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002; 300: 709-715
32. Kim MJ, Park KG, Lee KM, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005; 45: 552-556
33. Watanabe K, Ikeda S, Komatsu J, et al. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 2003; 92: 21-25
34. Zhao H, Quilley J, Montrose DC, et al. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and CAMP-dependent vasorelaxation following balloon angioplasty. Am J Physiol Heart Circ Physiol 2007; 292: H2973-H2981
35. Douglas JS, Jr, Holmes DR, Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832